pneumococcal vaccine 15-valent (Rx)

Brand and Other Names:Vaxneuvance
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

injection, suspension

  • 0.5mL prefilled syringe
  • Conjugated to carrier protein (diphtheria CRM197 protein)

Streptococcus pneumoniae Immunization

Streptococcus pneumoniae Immunization

Indicated for active immunization for prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae in adults aged ≥18 years

0.5 mL IM as a single dose

Dosage Modifications

Renal or hepatic impairment

  • Studies not conducted

Dosing Considerations

Vaccine serotypes include 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F

Serotypes 22F and 33F are not included in currently licensed pneumococcal conjugate vaccines and are commonly associated with invasive pneumococcal disease worldwide

Safety and efficacy not established

Next:

Interactions

Interaction Checker

and pneumococcal vaccine 15-valent

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            >10%

            All grades

            • Pain (55.1-75.8%)
            • Fatigue (18.1-34.3%)
            • Myalgia (15.7-28.8%)
            • Headache (13.4-26.5%)
            • Swelling (14.2-21.7%)
            • Erythema (7.9-15.1%)
            • Arthralgia (5.5-12.7%)

            1-10%

            Fever 38ºC to <38.5ºC (0.6-1.6%)

            Grade 3

            • Fatigue (1%)
            • Pain (1%)

            <1%

            Fever 38.5ºC to <39ºC (0.1-0.3%)

            Fever ≥39ºC (0.2%)

            Grade 3

            • Pain (0.8-0.9%)
            • Erythema, >10 cm (0.5-0.8%)
            • Headache (0.4-0.8%)
            • Myalgia (0.3-0.8%)
            • Fatigue (0.7%)
            • Arthralgia (0.2-0.4%)
            • Swelling, >10 cm (0.2-0.4%)
            Previous
            Next:

            Warnings

            Contraindications

            Severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or to diphtheria toxoid

            Cautions

            Some individuals with altered immunocompetence, including those receiving immunosuppressive therapy, may have reduced immune response

            Drug interaction overview

            • Immunosuppressive therapies may reduce immune response to vaccine
            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy

            No adequate and well-controlled studies have been conducted in pregnant women; data are insufficient to inform vaccine-associated risks in pregnancy

            Animal studies

            • Developmental toxicity studies in female rats administered a human dose have been conducted on 4 occasions (twice before mating, once during gestation, and once during lactation)
            • These studies revealed no evidence of harm to the fetus

            Lactation

            Data are not available to assess vaccine impact on milk production, its presence in breast milk, or its effects on breastfed children

            Consider developmental and health benefits of breastfeeding along with the mother’s clinical need for therapy and any potential adverse effects on breastfed children from the drug or from underlying maternal condition; for preventive vaccines, the underlying condition is susceptibility to disease prevented by the vaccine

            Pregnancy Categories

            A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA: Information not available.

            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Protection against invasive disease conferred mainly by opsonophagocytic killing of S pneumoniae

            Vaccine induces opsonophagocytic activity against the serotypes contained in vaccine

            Previous
            Next:

            Administration

            IM Preparation

            Hold syringe horizontally and shake vigorously immediately before administration to obtain an opalescent suspension

            Discard if it cannot be resuspended

            Inspect visually for particulate matter and discoloration; do not use if particulate matter or discoloration observed

            IM Administration

            For IM administration only

            Storage

            Refrigerate at 2-8ºC (36-46ºF)

            Do not freeze

            Protect from light

            Preservative-free suspension

            Tip cap and plunger stopper of prefilled syringe are not made with natural rubber latex

            Previous
            Next:

            Images

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
            Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.